Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pulmonary Hypoplasia Clear all
Not yet recruiting Phase 1 Interventional

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

NCT06067776
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Cetuximab, Osimertinib, Tucatinib
Biological · Drug
Lead sponsor
Jonathan Riess
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 2, 2026, 8:51 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

NCT05363280
View directory record Official record
Conditions
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
Interventions
AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
Drug
Lead sponsor
Advenchen Pharmaceuticals, LLC.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Weston, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 2, 2026, 8:51 PM EDT
Recruiting Not applicable Interventional

Safety and Efficacy of FETO in CDH: A Phase III Trial

NCT06884423
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Interventions
FETO with GoldBAL2 Balloon and BALTACCIBDPE100 Catheter
Device
Lead sponsor
Holly L Hedrick, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 2, 2026, 8:51 PM EDT
Completed Phase 1 Interventional

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

NCT01862081
View directory record Official record
Conditions
Breast Cancer, Non-small Lung Cancer
Interventions
Docetaxel, GDC-0032, Paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Tampa, Florida • Boston, Massachusetts • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 2, 2026, 8:51 PM EDT
Recruiting Phase 1 Interventional

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

NCT06917079
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
Interventions
BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 2, 2026, 8:51 PM EDT
Completed Phase 2 Interventional

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT00112346
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Cetuximab + platinum + gemcitabine, Platinum + Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
31
States / cities
Mobile, Alabama • Anchorage, Alaska • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 2, 2026, 8:51 PM EDT
Completed Phase 3 Interventional Results available

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

NCT04471428
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cabozantinib, Atezolizumab, Docetaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Palo Alto, California • San Diego, California • Santa Barbara, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 2, 2026, 8:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

NCT05134727
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
AZD5055, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 2, 2026, 8:51 PM EDT
Terminated Phase 3 Interventional

Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure

NCT00016523
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Respiratory Distress Syndrome (RDS), Sepsis, Pneumonia, Hypertension, Pulmonary
Interventions
Inhaled nitric oxide, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 120 Hours
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 2, 2026, 8:51 PM EDT
Terminated Not applicable Interventional Results available

An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System

NCT02067858
View directory record Official record
Conditions
Non Small Cell Lung Cancer, 4D CT
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Steven Burton
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 2, 2026, 8:51 PM EDT
Recruiting Phase 1 Interventional

Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia

NCT03723564
View directory record Official record
Conditions
Renal Failure Congenital, Congenital Renal Anomaly Nos, Renal Agenesis and Dysgenesis, Lower Urinary Tract Obstructive Syndrome
Interventions
Lactated Ringers Solution for Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 2, 2026, 8:51 PM EDT
Completed Phase 2 Interventional Results available

Milrinone in Congenital Diaphragmatic Hernia

NCT02951130
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
Interventions
Milrinone, Placebo (5% Dextrose)
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
0 Hours to 168 Hours
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 2, 2026, 8:51 PM EDT
Completed Not applicable Interventional

Strides for Life I: Increasing Physical Activity in Stage 1 Lung Cancer Patients

NCT02755883
View directory record Official record
Conditions
Lung Cancer
Interventions
Physical activity plus positive affect, Physical activity plus education
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 110 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 2, 2026, 8:51 PM EDT
Recruiting Not applicable Interventional

Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)

NCT03138863
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary Artery Hypertension
Interventions
BALT GoldbBAL2 Detachable Balloon, Catheter System
Device
Lead sponsor
Rodrigo Ruano
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Miami, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 2, 2026, 8:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Liquid Biopsy for Early Non-small Lung Cancer Detection

NCT05462795
View directory record Official record
Conditions
Non Small-cell Lung Cancer
Interventions
Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule, Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection, Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer, Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 2, 2026, 8:51 PM EDT
Recruiting Phase 2 Interventional

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

NCT05068232
View directory record Official record
Conditions
Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer
Interventions
Ablative Radiation, Durvalumab, Etoposide, Carboplatin
Radiation · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 2, 2026, 8:51 PM EDT
Completed Phase 2 Interventional Results available

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

NCT05054725
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
RMC-4630, Sotorasib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
23
States / cities
Fort Myers, Florida • Plantation, Florida • Saint Augustine, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 2, 2026, 8:51 PM EDT
Terminated No phase listed Observational

Afatinib Genomic Landscape

NCT02491775
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-small Lung Cancer
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 2, 2026, 8:51 PM EDT
Recruiting Phase 2 Interventional

A Study of Sotorasib in People With Non-Small Cell Lung Cancer

NCT06582771
View directory record Official record
Conditions
Non Small Lung Cancer
Interventions
Sotorasib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 2, 2026, 8:51 PM EDT
Completed Not applicable Interventional

Fetal Surgery for Moderate Left Sided Congenital Diaphragmatic Hernia.

NCT00763737
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Fetal Surgery, Pulmonary Hypoplasia
Interventions
Fetoscopic Endoluminal Tracheal Occlusion
Procedure
Lead sponsor
University Hospital, Gasthuisberg
Other
Eligibility
18 Years and older · Female only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 2, 2026, 8:51 PM EDT
Completed Phase 3 Interventional Results available

Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer

NCT00390806
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
HYCAMTIN, oral capsules, Radiation
Drug · Radiation
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
46
States / cities
Birmingham, Alabama • Glendale, Arizona • Hot Springs, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 2, 2026, 8:51 PM EDT
Terminated Phase 1 Interventional

(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer

NCT02132403
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
BTH1704, IMPRIME PGG, Gemcitabine
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 2, 2026, 8:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

NCT07629960
View directory record Official record
Conditions
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Interventions
BLU-924
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Sarasota, Florida • Tampa, Florida • Baton Rouge, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 2, 2026, 8:51 PM EDT
Terminated Phase 1 Interventional

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT00369551
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Stage II Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
3-dimensional conformal radiation therapy, paclitaxel, bevacizumab, carboplatin, laboratory biomarker analysis
Radiation · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 2, 2026, 8:51 PM EDT